Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

67.07 +1.38 (+2.10%)
Streaming Delayed Price Updated: 10:39 AM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
The Great Rotation: Small-Caps Lead 2026 Market Charge as Tech Giants Stumble
The first week of 2026 has delivered a definitive verdict on the next phase of the bull market: the era of mega-cap dominance is yielding to the rise of the small-cap. In a dramatic "Great Rotation,"... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Why Did ARWR Stock Surge Over 15% Pre-Market Today? ↗
The preliminary results from Phase 1/2a clinical trials of the company’s RNA interference (RNAi) therapies suggest the treatments may reduce body fat and improve metabolic health in patients,... 
Via Stocktwits
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
Arrowhead Pharmaceuticals Stock Jumps 22% After Morgan Stanley Hikes Price Target ↗
Via Stocktwits
Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’ ↗
Via Stocktwits
News headline image
Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today ↗
These are historic days for the company, following its first FDA approval. 
Via The Motley Fool
News headline image
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Reports Strong Q4 2025 Revenue Beat and First FDA Approval ↗
Arrowhead Pharmaceuticals exceeded Q4 2025 revenue expectations, driven by its first FDA-approved drug and strong collaborations, marking its shift to a commercial-stage company. 
Via Chartmill
News headline image
Arrowhead (ARWR) Q4 2025 Earnings Call Transcript ↗
Arrowhead (ARWR) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The Announcement ↗
Via Stocktwits
News headline image
FDA Clears Arrowhead Pharma's First-Ever Home Injection For Rare Fat Disorder ↗
Arrowhead Pharmaceuticals won FDA approval for Redemplo (plozasiran), an siRNA drug reducing high triglycerides in adults with rare FCS. 
Via Benzinga
News headline image
CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial ↗
CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its gene editing platform. 
Via Benzinga
News headline image
Privium Fund Management Sells Into Strength in Pharma Stock ↗
Privium Fund Management Sells Into Strength in Pharma Stock 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals ↗
Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action. 
Via Benzinga
News headline image
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal ↗
The announcement of a landmark deal with a pharmaceutical giant validates Arrowhead's technology. 
Via The Motley Fool
News headline image
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion ↗
Arrowhead Pharmaceuticals and Novartis inked a licensing deal Tuesday for an experimental Parkinson's drug. 
Via Investor's Business Daily
News headline image
This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week ↗
H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s closing price on Wednesday. 
Via Stocktwits
News headline image
Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives ↗
Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquified its entire stake in the company. 
Via Investor's Business Daily
Topics Death
News headline image
Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial ↗
Sarepta sold part of its Arrowhead stake to help fund the milestone payment, while also outlining plans to release early data from two genetic therapy programs in the second half of 2025. 
Via Stocktwits
News headline image
Arrowhead (ARWR) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Arrowhead (ARWR) Q3 Revenue Drops 41% ↗
Via The Motley Fool
News headline image
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Reports Mixed Q3 2025 Results with Revenue Beat but Wider-Than-Expected Loss ↗
Arrowhead Pharmaceuticals reported mixed Q3 2025 results, beating revenue estimates but missing on EPS. Stock fell 5.3% as higher R&D costs widened losses. Key pipeline updates include plozasiran NDA... 
Via Chartmill
News headline image
Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On? ↗
Stock of Sarepta Therapeutics Inc. (NASDAQ: SRPT) surged 38.89% in Tuesday pre-market following the U.S. Food and Drug Administration's (FDA) recommendation to lift the voluntary hold on Elevidys,... 
Via Benzinga
News headline image
FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys ↗
FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment. 
Via Benzinga
News headline image
Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy ↗
Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients. 
Via Benzinga
News headline image
Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe ↗
Shares are down another double-digit percentage after bad news continued piling on for gene therapy Elevidys. 
Via Investor's Business Daily
Topics Death
News headline image
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review ↗
Sarepta pauses U.S. Elevidys shipments to complete FDA-requested safety label updates, aiming to resume distribution in the fourth quarter. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.